Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089712 | 0.94 | LTA4H (0.40) | LTA4HPPARGPPARAMEN1KMT2A | |
| SCHEMBL36030 | 0.94 | MEN1 (0.41) | LTA4HMEN1KMT2ATSHR | |
| SCHEMBL36226 | 0.88 | TSHR (0.40) | LTA4HMEN1KMT2ATSHRHRH3 | |
| SCHEMBL14087660 | 0.87 | LTA4H (0.37) | LTA4HSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL14075160 | 0.84 | HDAC3 (0.45) | LTA4HHRH3 | |
| SCHEMBL36335 | 0.83 | TSHR (0.37) | SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL2850237 | 0.83 | KCNA3 (0.43) | LTA4H | |
| SCHEMBL3054832 | 0.83 | MEN1 (0.39) | LTA4HMEN1KMT2ATSHR | |
| SCHEMBL36036 | 0.82 | TSHR (0.45) | SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL1127852 | 0.82 | TSHR (0.39) | MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100136300-A1 | CURABLE COMPOSITION, INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATERIAL, METHOD OF PRODUCING PLANOGRAPHIC PRINTING PLATE, PLANOGRAPHIC PRINTING PLATE AND OXETANE COMPOUND | FUJIFILM CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100136300-A1 | CURABLE COMPOSITION, INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATERIAL, METHOD OF PRODUCING PLANOGRAPHIC PRINTING PLATE, PLANOGRAPHIC PRINTING PLATE AND OXETANE COMPOUND | FUJIFILM CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-1757635-B1 | Curable ink comprising modified oxetane compound | FUJIFILM CORP (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20070049651-A1 | Curable composition, ink composition, inkjet recording method, printed material, method of producing planographic printing plate, planographic printing plate, and oxcetane compound | FUJI PHOTO FILM CO., LTD. | 2007-03-01 | — | — | US | disclosed |
| US-20070049651-A1 | Curable composition, ink composition, inkjet recording method, printed material, method of producing planographic printing plate, planographic printing plate, and oxcetane compound | FUJI PHOTO FILM CO., LTD. | 2007-03-01 | — | — | US | disclosed |
| EP-1757635-A1 | Curable modified oxetane compound and ink composition comprising it | Fuji Photo Film Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136300-A1 | CURABLE COMPOSITION, INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATERIAL, METHOD OF PRODUCING PLANOGRAPHIC PRINTING PLATE, PLANOGRAPHIC PRINTING PLATE AND OXETANE COMPOUND | CCNT1, ACVR2B, ACVR1B | LTA4H 2536/4885PLA2G2A 2856/4885SMN1; SMN2 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.